NEW YORK (GenomeWeb) – Premaitha Health today said that Antisel will distribute the firm's Iona non-invasive prenatal test to clinical laboratories in Greece.

The Manchester, UK-based firm said that labs in Greece currently have to send their samples to central labs in the US and China for NIPT screening. The agreement with Antisel, which is based Athens, Greece, will provide these labs with local NIPT screening, allowing them "to take advantage of the test's time to result of just three days," Premaitha said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Sponsored by

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.